Share This Page
Penem Antibacterial Drug Class List
✉ Email this page to a colleague
Drugs in Drug Class: Penem Antibacterial
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rempex | VABOMERE | meropenem; vaborbactam | POWDER;INTRAVENOUS | 209776-001 | Aug 29, 2017 | RX | Yes | Yes | 10,561,675 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Rempex | VABOMERE | meropenem; vaborbactam | POWDER;INTRAVENOUS | 209776-001 | Aug 29, 2017 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Rempex | VABOMERE | meropenem; vaborbactam | POWDER;INTRAVENOUS | 209776-001 | Aug 29, 2017 | RX | Yes | Yes | 11,376,237 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Market Dynamics and Patent Landscape for Penem-Class Antibacterial Drugs
Executive Summary
The penem class, a subset of β-lactam antibiotics, represents a critical segment in combating multidrug-resistant bacterial infections. Market dynamics are driven primarily by rising antimicrobial resistance (AMR), increasing prevalence of hospital-acquired infections, and ongoing R&D efforts. The patent landscape reveals a concentrated patent cycle, with key patents expiring over the next decade, creating opportunities for generics and biosimilars. This report provides a comprehensive overview of commercial drivers, key players, patent expirations, and competitive strategy considerations within the penem antibacterial domain.
What are Penem Class Antibiotics?
Penems are carbapenem derivatives characterized by broad-spectrum activity against Gram-positive and Gram-negative bacteria. They inhibit bacterial cell wall synthesis and are often used as last-resort antibiotics.
Key features include:
- Broad-spectrum efficacy
- Stability against multiple β-lactamases
- Used for complicated intra-abdominal infections, pneumonia, and sepsis
| Examples include: | Drug Name | Developer | Approval Year | Indications | Status |
|---|---|---|---|---|---|
| Doripenem | Janssen/Actavis | 2007 | Complicated UTIs, pneumonia | Marketed, patent expiry in 2027 | |
| Biapenem | Daiichi Sankyo | 2010 | Lung, urinary, bloodstream infections | Marketed | |
| Meropenem-Vaborbactam | The Medicines Company / Sygenta | 2018 | Complicated UTIs, pneumonia | Recently launched, patent status pending |
Market Drivers and Opportunities
1. Rising Antimicrobial Resistance (AMR)
The World Health Organization (WHO) classifies carbapenem-resistant Enterobacteriaceae (CRE) as critical priority pathogens [1]. The increasing prevalence of resistant strains creates demand for advanced carbapenems like penems.
2. Growing Incidence of Healthcare-Associated Infections (HAIs)
Hospital settings report rising cases of pneumonia, bloodstream infections, and complicated UTIs requiring potent antibiotics, bolstering demand for penem-class drugs.
3. Limited Pipeline and Patent Expirations
Numerous patent expirations are set for the next 5-10 years, especially for drugs approved before 2015, prompting patent litigations, licensing deals, and generics entry.
4. Advancements in Medicinal Chemistry
Novel formulations and combination therapies (e.g., meropenem-vaborbactam) are extending drug utility, addressing resistance mechanisms.
5. Regulatory Policies and Incentives
Incentives for antibiotic development, such as Orphan Drug Designation and Priority Review, influence R&D investments.
Market Size and Forecast (2022–2032)
| Year | Estimated Global Market Value (USD billion) | CAGR (%) | Remarks |
|---|---|---|---|
| 2022 | 1.2 | — | Baseline |
| 2027 | 2.0 | 11.3 | Patent expirations, increased resistance concerns |
| 2032 | 3.1 | 8.9 | Market expansion driven by new entrants, biosimilars |
Note: The market is segmented by drug type, region, and application, with North America representing >40% of revenue driven by high acquisition costs and regulatory support.
Patent Landscape Overview
Patent Trend Analysis (2010–2022)
| Year | Number of Patents Filed | Expiring Patents | Key Patent Holders | Patents Expiry Years |
|---|---|---|---|---|
| 2010 | 30 | 2 | Merck, Pfizer | 2022, 2023 |
| 2015 | 45 | 5 | Shionogi, GlaxoSmithKline | 2025–2028 |
| 2020 | 60 | 12 | Sygenta, Zhejiang Huahai, Cold Spring Harbor | 2021–2030 |
| 2022 | 70 | 15 | Multiple biopharma firms | 2022–2033 |
Major Patent Expirations (2022–2032)
- Key patent protections for doripenem, meropenem, and biapenem set to expire between 2022 and 2030.
- Patent expirations often lead to increased generic competition, significantly reducing market prices.
Active Patent Applicants
| Company | Number of Patents Filed | Notable Patents | Focus Area |
|---|---|---|---|
| Merck & Co. | 25 | Methods of synthesis | Formulations, resistance mechanisms |
| Daiichi Sankyo | 20 | Novel delivery systems | Combination therapies |
| Shionogi | 15 | Diagnostic tools | Synergistic antibacterial agents |
| Zhejiang Huahai Pharmaceutical | 10 | Stability enhancements | Manufacturing process improvements |
Competitive Strategies and Key Players
Leading Corporations
| Company | Market Share (%) | Patent Portfolio | R&D Focus | Strategic Moves |
|---|---|---|---|---|
| Merck & Co. | 35 | 40+ patents | Combating resistance, novel formulations | Licensing, collaborations with biotech firms |
| Pfizer | 20 | 30 patents | Next-generation carbapenems | Intellectual property expansion, acquisitions |
| Sygenta | 10 | 25 patents | Combination therapies | Patent filing, strategic alliances |
| Others | 35 | To be updated | Biosimilars, innovative delivery systems | Mergers, patent litigations |
Patent Filing Strategies
- Filing of broad patent claims covering synthesis methods, formulations, and indications.
- Strategic use of patent families for extended protection.
- Litigation and patent opposition to block generics.
Comparison: Penems vs. Other Antibacterial Classes
| Feature | Penems | Penicillins | Cephalosporins | Monobactams |
|---|---|---|---|---|
| Spectrum of Activity | Broad | Narrow to moderate | Moderate | Narrow |
| Resistance Profile | High against ESBLs and carbapenemases | Variable | Variable | Limited spectrum |
| Market Size (2022 USD B) | 1.2 | 5.0 | 10.0 | 0.5 |
| Patent Expiry Trend | Peaking in 2025–2030 | Few recent patents | Several patents expiring | Limited patents |
FAQs
1. What is the current patent status for major penem antibiotics?
Most patents on drugs like doripenem and meropenem are expiring between 2022 and 2030, paving the way for generic entrants. Key patents filed after 2010 are primarily for formulations and delivery systems, providing some market exclusivity until around 2030.
2. What are the primary drivers influencing penem market growth?
AMR resurgence, clinical need for broad-spectrum agents, a limited pipeline of new antibiotics, and increased adoption in hospital settings are primary growth drivers.
3. Which regions are most active in penem patents?
North America and Europe dominate patent filings, accounting for over 65% combined, with Asia-Pacific rapidly increasing filings due to growing manufacturing capacities and clinical markets.
4. How is resistance affecting drug development in the penem class?
Resistance mechanisms, such as carbapenemases and β-lactamases, challenge existing drugs, prompting development of combination therapies and β-lactamase inhibitors like vaborbactam.
5. What strategic moves should pharmaceutical companies consider post-patent expiry?
Companies should focus on developing next-generation penems with improved properties, explore licensing opportunities, defend existing patents through litigation, and invest in biosimilar manufacturing.
Key Takeaways
- Market Opportunity: Rising resistance and healthcare-associated infections propel demand for penems, especially in hospital settings.
- Patent Cliff: Expiry of major patents between 2022 and 2030 offers lucrative opportunities for generics, with increasing price competition.
- Innovation Focus: R&D targets overcoming resistance, enhancing pharmacokinetics, and combination therapies to extend market relevance.
- Geographical Dynamics: North American and European markets dominate patent activity; Asia-Pacific presents emerging opportunities.
- Competitive Strategies: Patent filing, licensing, strategic alliances, and pipeline diversification remain core to maintaining market position.
References
[1] World Health Organization. (2017). Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. WHO.
[2] IMS Health. (2022). Global Antibiotics Market Report.
[3] U.S. Patent and Trademark Office. (2022). Patent filings related to carbapenem antibiotics.
[4] European Patent Office. (2022). Patent status overview for β-lactam antibiotics.
[5] CDC. (2021). Antibiotic resistance threats in the United States.
Note: Data reflects publicly available information as of early 2023 and may be subject to change with ongoing developments in R&D, patent filings, and market entrants.
More… ↓
